PPD, Inc. (PPD) |
| 47.28 0 (0%) 04-24 15:47 |
| Open: | 47.32 |
| High: | 47.4 |
| Low: | 47.24 |
| Volume: | 1,868,187 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 47.40 |
| Resistance 1: | 47.34 |
| Pivot price: | 47.28 |
| Support 1: | 47.24 |
| Support 2: | 39.30 |
| 52w High: | 47.41 |
| 52w Low: | 31.54 |
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
| EPS | 1.000 |
| Book Value | -1.210 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.537 |
| Profit Margin (%) | 6.19 |
| Operating Margin (%) | 11.37 |
| Return on Assets (ttm) | 6.4 |
| Return on Equity (ttm) | 0.0 |
Tue, 16 Dec 2025
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Tue, 30 Sep 2025
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PR Newswire
Mon, 18 Aug 2025
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) - GlobeNewswire
Sun, 09 Jul 2023
PPD - Carlyle
Thu, 09 Dec 2021
Thermo Fisher acquires clinical research services provider PPD for $17.4bn - Pharmaceutical Technology
Wed, 08 Dec 2021
Thermo Fisher Completes Purchase Of PPD - WilmingtonBiz
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |